Background
Many patients with advanced stages of cardiac disease need cardiac surgery, which can lead to severe left ventricular dysfunction and, in particular, postoperative low cardiac output syndrome (LCOS) [
1]. These conditions may lead to increased morbidity, multiple organ failure and death [
2]. Strategies to address the syndrome include the use of inotropic agents and an intra-aortic balloon pump (IABP). Unfortunately, most inotropic agents increase postoperative morbidity and mortality rates due to increased myocardial oxygen consumption [
3].
Levosimendan is an inotropic agent that enhances myocardial contractility without increasing myocardial oxygen demand in patients with low cardiac systolic dysfunction [
4]. Clinical studies have reported that levosimendan therapy improves survival in patients undergoing cardiac surgery [
5,
6]. Previous meta-analyses of small randomized trials have shown that levosimendan is associated with survival benefits among patients undergoing cardiac surgery [
7,
8]. However, recently published larger-scale trials did not provide evidence for a similar benefit from levosimendan [
9‐
11].
The objective of this meta-analysis was to assess the survival benefits of levosimendan in patients undergoing cardiac surgery. Previous meta-analyses showed that patients with low ejection fraction (EF) benefit more from levosimendan therapy than patients with normal EF [
7,
8]. Therefore, we performed subgroup analyses according to the preoperative EF of enrolled patients.
Methods
Eligibility criteria
We included trials with the following features:
1)
Type of study: randomized controlled clinical trials
2)
Population: patients undergoing cardiac surgery
3)
Intervention: patients receiving intravenous levosimendan
4)
The following outcomes were included
a)
Primary outcomes: 30-day mortality or in-hospital mortality.
b)
Secondary outcomes: requiring renal replacement therapy, the duration of mechanical ventilation, and intensive care unit (ICU) length of stay.
c)
Serious adverse events: the occurrence of postoperative arrhythmia and hypotension.
Search strategy for the identification of studies
We conducted a search of the Medline, Elsevier, Cochrane (Central), Web of Science and ClinicalTrials.gov databases for studies investigating the perioperative use of levosimendan in patients undergoing cardiac surgery. When searching each database, the term “levosimendan” was combined with the Cochrane highly sensitive search strategy for identifying randomized trials [
12]. Searches were limited to English and included all publications in the available databases through 20 April 2017.
Study selection
Two reviewers independently screened abstracts and titles to determine whether the studies met the inclusion criteria. The full texts of the articles were then reviewed independently in accordance with the inclusion and exclusion criteria. Studies that reported randomized clinical trials of the preoperative or postoperative administration of levosimendan in patients undergoing cardiac surgery were included. “low-EF studies” were defined as studies that limited their analysis to patients with a preoperative EF ≦40% or enrolled patients with a preoperative mean EF ≦40%. The remaining studies were designated “preserved-EF studies” [
13]. Any discrepancies were resolved by reaching a consensus on the inclusion or exclusion of a study by discussion with a third reviewer.
Data extraction and management
Two authors independently extracted the data using a standardized data extraction protocol. Any disagreements between the two reviewers were resolved through discussion, after which consensus was reached. Some means and standard deviations of the patients’ duration of mechanical ventilation and ICU length of stay data were estimated according to the method described by Hozo [
14]. Information including trial characteristics, criteria for inclusion and exclusion, the method of intervention and outcomes was extracted from the included studies.
Methodological quality assessment
Two reviewers independently completed a risk of bias assessment following the instructions of the Cochrane Collaboration tool for systematic reviews of interventions [
12]. The items are defined as sequence generation; allocation concealment; blinding; incomplete outcome reporting; and other risks of bias. Each item included in the Cochrane Collaboration tool was reported in terms of unclear, low or high risk of bias. Disagreements were resolved via discussion, and a third reviewer mediated situations where disagreements occurred.
Trial sequential analysis
We perform a trial sequential analysis (TSA) to prevent the risk of random error from being increased by repeated updates. We used TSA-adjusted random-effects modes to pool results from the included studies for primary outcomes. A one-sided TSA was conducted to maintain a 5% risk of type I error and 80% power. Furthermore, we used the estimated function to calculate the required information size.
Statistical analysis
For the meta-analysis, data from the included studies were analyzed using Review Manager (Review Manager, version 5.3), and pooled risk ratios for dichotomous data and mean differences for continuous data with 95% CIs were calculated. The statistical heterogeneity of the data was quantified using the Mantel-Haenszel chi-square test and the I
2 test. Any obvious heterogeneity was predefined as p < 0.05 using the Mantel-Haenszel chi-square test or I
2 > 50%. Furthermore, publication bias was assessed using funnel plot techniques.
Discussion
Levosimendan is used to reduce mortality in patients undergoing cardiac surgery; however, recently published large-scale trials [
9‐
11] did not provide evidence for this benefit. In this meta-analysis of randomized clinical trials of levosimendan therapy in patients undergoing cardiac surgery, the results showed that levosimendan therapy reduced the risk of death in single-center trials and in trials of inferior quality but that this benefit of levosimendan on survival was not shown in multicentric or high-quality trials. However, levosimendan therapy was associated with reduced mortality in patients with preoperative ventricular dysfunction. Furthermore, in these patients, levosimendan therapy results in less renal replacement therapy and shorter stays in the ICU.
Previous meta-analyses of small randomized trials showed a significant reduction in mortality among patients who received levosimendan treatment compared to controls among patients undergoing cardiac surgery [
7,
8]. However, the benefit of levosimendan on survival was not shown in recent large-scale trials [
9‐
11]. In our updated analysis, we included two recently published large-scale studies. Similar to a previous meta-analysis [
7], our result showed that levosimendan therapy was associated with a significant reduction in mortality in patients undergoing cardiac surgery. However, subgroup analyses showed that levosimendan therapy did not reduce the risk of death in multicentric or high-quality trials. Eligible patients in many multicentric or high-quality trials had ventricular systolic dysfunction [
10,
15], while patients included in the other trials had preserved left ventricular systolic function with EF exceeding 40% [
8,
9,
12,
19]. Previous studies showed that levosimendan improves clinical outcomes in patients with left ventricular dysfunction [
16,
25]. Patients with reduced EF may benefit more from levosimendan therapy. Therefore, we performed subgroup analyses of high-quality trials according to EF. Interestingly, patients with preoperative better left ventricular systolic function did not benefit from levosimendan therapy while levosimendan therapy was associated with a significant reduction in mortality in patients with preoperative low EF. Therefore, our meta-analysis indicates that levosimendan is only recommended for use in patients undergoing cardiac surgery with preoperative poor left ventricular function.
Postoperative AKI is a common complication in patients undergoing cardiac surgery [
27]. Some studies have reported that levosimendan therapy in patients undergoing cardiac surgery is associated with lower renal replacement therapy and a shorter duration of mechanical ventilation [
5,
28,
29]. However, controversial or negative results on the effect of levosimendan have been reported [
18]. Our analysis showed a significant reduction in the risk of renal replacement therapy with levosimendan therapy in patients undergoing cardiac surgery. In addition, we also found that levosimendan therapy reduced mechanical ventilation duration in patients undergoing cardiac surgery. Subgroup analysis indicated that these benefits were confined to low-EF studies. Levosimendan might improve renal function in cardiac surgery due to its ability to improve cardiac systolic function and systemic hemodynamics [
30]. In acute decompensated heart failure, levosimendan has an immediate renoprotective effect, which is mediated by an increase in renal blood flow resulting from selective renal arterial and venous vasodilating action [
31]. One study also indicated that levosimendan therapy induced vasodilation, preferentially of preglomerular resistance vessels, thereby increasing both renal blood flow and glomerular filtration rate without jeopardizing renal oxygenation after cardiac surgery with cardiopulmonary bypass [
32].
The improvement in cardiac systolic function induced by levosimendan is due to two mechanisms – vasodilation and increased contractility [
33]. In this meta-analysis, postoperative hypotension was documented in four trials (1600 patients). Pooled analysis showed no association between levosimendan and postoperative hypotension. A possible reason for this may be that the reduction in systemic vascular resistance is compensated for by an increased cardiac index. Since most of these hypotension episodes often occurred following the administration of a loading dose, hypotension may be avoided by eliminating the loading dose while the favorable hemodynamic effects of levosimendan can be obtained through continuous infusion [
23,
34].
With regard to other adverse effects, postoperative arterial fibrillation was also observed. Our analysis showed that levosimendan therapy did not increase the incidence of postoperative arterial fibrillation. However, levosimendan use significantly increased the incidence of hypotension in patients with preoperative ventricular systolic dysfunction. Although levosimendan can be considered to be a well-tolerated agent that can provide an important treatment option for cardiac systolic dysfunction following cardiac surgery [
35,
36], levosimendan should be used with caution in patients with hemodynamic instability.
There were several limitations in this meta-analysis. Levosimendan dosing and drug-delivery methods varied between the trials. Four studies used an infusion without a bolus, and two studies used bolus dosing without an infusion. Additionally, we performed a subgroup analysis according to the mean EF. As a result, some studies [
9,
18,
19] that were classified as preserved-EF studies included some patients with EF ≦40%. Furthermore, we were unable to access individual patient data. Therefore, some means and standard deviations of the patients’ ICU length of stay data were estimated according to the method described by Hozo [
14].
Conclusion
In summary, the available evidence from our updated meta-analysis suggests that levosimendan therapy reduced the risk of death in single-center trials and in trials of inferior quality, but there was no benefit of levosimendan on survival in multicentric and in high-quality trials. However, levosimendan therapy was associated with reduced mortality in patients with preoperative ventricular systolic dysfunction. Furthermore, in these patients, levosimendan therapy resulted in less renal replacement therapy and shorter ICU stays. However, patients with normal left ventricular systolic function cannot benefit from levosimendan therapy. Additionally, levosimendan should be used with caution in patients with hemodynamic instability because levosimendan use significantly increased the incidence of hypotension in patients with preoperative ventricular systolic dysfunction who were undergoing cardiac surgery.